Depressive disorders refer to a syndrome or set of symptoms that primarily affect the affective sphere: pathological sadness, decay, irritability or mood disorder, which may decrease work performance or limit routine activity, regardless of knowledge or not of its cause. There is a wide variety of antidepressant medications and psychotherapies that can be used to treat depressive disorders. The lack of effect of pharmacological treatment of depression may be in large part due to genetic causes, since the variation in the human genome is one of the most important factors responsible for modulating individual response to medications.
The genetic profile FG – Neuro Depression studies the main metabolizing enzymes, carriers and targets involved in the activity of antidepressant drugs. The analysis provides relevant information about the 15 most used drugs, based on the study of 20 genetic polymorphisms described in the scientific literature, present in the enzymes of the cytochrome P450 system: CYP2D6, CYP2C19.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients with drug side effects
• Patients in whom pharmacological treatments do not show the expected results.
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.